You just read:

Phase 2a Clinical Study Data of AJM300, Oral alpha 4 Integrin Antagonist, Will Be Presented in Digestive Disease Week 2014

News provided by

Ajinomoto Pharmaceuticals Co., Ltd.

Apr 16, 2014, 01:00 ET